|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim YH and Mishima M: Consolidation
chemotherapy after concurrent chemoradiotherapy in patients with
stage III non-small-cell lung cancer. J Clin Oncol. 34:7672016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kwong A, Shin VY, Au CH, Law FB, Ho DN, Ip
BK, Wong AT, Lau SS, To RM, Choy G, et al: Evaluation on the
mutation screening by next-generation sequencing in hereditary
breast and ovarian cancer: Implementation of recurrent mutation
panel. Cancer Res. 76(4 Suppl): P2-09-202016. View Article : Google Scholar
|
|
5
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chung C: Tyrosine kinase inhibitors for
epidermal growth factor receptor gene mutation-positive non-small
cell lung cancers: An update for recent advances in therapeutics. J
Oncol Pharm Pract. 22:461–476. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shea M, Costa DB and Rangachari D:
Management of advanced non-small cell lung cancers with known
mutations or rearrangements: Latest evidence and treatment
approaches. Ther Adv Respir Dis. 10:113–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gorgisen G, Pehlivanoglu S, Ozes D and
Ozes ON: Personalized treatment options in non-small cell lung
cancer. J Managed Care Med. 1:2014.
|
|
12
|
Pollock PM and Meltzer PS: A genome-based
strategy uncovers frequent BRAF, mutations in melanoma. Cancer
Cell. 2:5–7. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stephens RM, Sithanandam G, Copeland TD,
Kaplan DR, Rapp UR and Morrison DK: 95-kilodalton B-Raf
serine/threonine kinase: Identification of the protein and its
major autophosphorylation site. Mol Cell Biol. 12:3733–3742. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Santarpia L, Lippman SM and El-Naggar AK:
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carlino MS, Long GV, Kefford RF and Rizos
H: Targeting oncogenic BRAF and aberrant MAPK activation in the
treatment of cutaneous melanoma. Crit Rev Oncol Hematol.
96:385–398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Planchard D, Kim TM, Mazieres J, Quoix E,
Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, et al:
Dabrafenib in patients with BRAF(V600E)-positive advanced
non-small-cell lung cancer: A single-arm, multicentre, open-label,
phase 2 trial. Lancet Oncol. 17:642–650. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carter J, Tseng LH, Zheng G, Dudley J,
Illei P, Gocke CD, Eshleman JR and Lin MT: Non-p.V600E BRAF
mutations are common using a more sensitive and broad detection
tool. Am J Clin Pathol. 144:620–628. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen D, Zhang LQ, Huang JF, Liu K, Chuai
ZR, Yang Z, Wang YX, Shi DC, Liu Q, Huang Q and Fu WL: BRAF
mutations in patients with non-small cell lung cancer: A systematic
review and meta-analysis. PLoS One. 9:e1013542014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He PJ, Xia HL, Fu M, et al: Detection of
EGFR KRAS, BRAF, EML4-ALK fusion genes by ARMS and NGS in patients
with non-small cell lung cancer. Acta Univ Med Anhui. 52:1553–1558.
2017.In Chinese.
|
|
20
|
Gao J, Wu H, Wang L, Zhang H, Duan H, Lu J
and Liang Z: Validation of targeted next-generation sequencing for
RAS mutation detection in FFPE colorectal cancer tissues:
Comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
BMJ Open. 6:e0095322016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lindeman NI, Cagle PT, Beasley MB, Chitale
DA, Dacic S, Giaccone G, Enkins RB, Kwiatkowski DJ, Saldivar JS,
Squire J, et al: Molecular testing guideline for selection of lung
cancer patients for EGFR and ALK tyrosine kinase inhibitors:
Guideline from the College of American Pathologists, International
Association for the study of lung cancer, and association for
molecular pathology. Arch Pathol Lab Med. 137:2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roma C, Esposito C, Rachiglio AM, Pasquale
R, Iannaccone A, Chicchinelli N, Franco R, Mancini R, Pisconti S,
De Luca A, et al: Detection of EGFR mutations by TaqMan mutation
detection assays powered by competitive allele-specific TaqMan PCR
technology. Biomed Res Int. 2013:3850872013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Syed YY: Therascreen® EGFR RGQ
PCR Kit: A companion diagnostic for afatinib and gefitinib in
non-small cell lung cancer. Mol Diagn Ther. 20:191–198. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rosamaria P, De Summa S, Strippoli S,
Pilato B, Azzariti A, Guida G, Guida M and Tommasi S: The next
generation of metastatic melanoma: Uncovering the genetic variants
for anti-BRAF therapy response. Oncotarget. 7:25135–25149.
2016.PubMed/NCBI
|
|
25
|
Baudhuin LM, Donato LJ and Uphoff TS: How
novel molecular diagnostic technologies and biomarkers are
revolutionizing genetic testing and patient care. Expert Rev Mol
Diagn. 12:25–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sharma D, Lather M, Dykes CL, Dang AS,
Adak T and Singh OP: Disagreement in genotyping results of drug
resistance alleles of the Plasmodium falciparum dihydrofolate
reductase (Pfdhfr) gene by allele-specific PCR (ASPCR) assays and
Sanger sequencing. Parasitol Res. 115:323–328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shao D, Lin Y, Liu J, Wan L, Liu Z, Cheng
S, Fei L, Deng R, Wang J, Chen X, et al: A targeted next-generation
sequencing method for identifying clinically relevant mutation
profiles in lung adenocarcinoma. Sci Rep. 6:223382016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bronte G, Silvestris N, Castiglia M,
Galvano A, Passiglia F, Sortino G, Cicero G, Rolfo C, Peeters M,
Bazan V, et al: New findings on primary and acquired resistance to
anti-EGFR therapy in metastatic colorectal cancer: Do all roads
lead to RAS? Oncotarget. 6:24780–24796. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bao Y, Ching B, Mouanoutoua M, Yu W, Keys
D, Desai S and Stevens J: Cancer biomarker research using castPCR
technology. Cancer Res. 72(8 Suppl): S21002012. View Article : Google Scholar
|
|
30
|
Didelot A, Le CD, Luscan A, Cazes A,
Pallier K, Emile JF, Laurent-Puig P and Blons H: Competitive allele
specific TaqMan PCR for KRAS BRAF and EGFR mutation detection in
clinical formalin fixed paraffin embedded samples. Exp Mol Pathol.
92:275–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li K, Woo C, Mouanoutoua M, Moy B, Langit
E, Brzoska P, You X, Desai S, Keys D, Stevens J, et al: Validation
of the Ion AmpliSeq™ comprehensive cancer panel (CCP) using
castPCR™ technologies. Cancer Res. 73(8 Suppl): S42182013.
View Article : Google Scholar
|
|
32
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumors. 7th. Wiley-Blackwell;
Oxford: 2009
|
|
33
|
TaqMan® Mutation Detection
Assay Competitive Allele-Specific TaqMan® PCR.
Publication Part Number 4467011 Rev. B. https://tools.thermofisher.com/content/sfs/manuals/cms_095873.pdfApril.
2012
|
|
34
|
Tan R and Brzoska P: Direct detection of
rare circulating tumor cells in blood by CastPCR. J Biomol Tech.
21(3 Suppl): S302010.
|
|
35
|
Tan R, Brzoska P and Chen C: Detection of
rare mutations in patient samples by comparative allele-specific
TaqMan® assay-based PCR (CastPCR). Cancer Res. 70(8
Suppl): S21172010. View Article : Google Scholar
|
|
36
|
Bao Y, Merrill D, Corre DL, Sproul S,
Ching B, Casuga I, Sapinoso L, Desai S, Petraroli RP, Deng D, et
al: Accurate and sensitive detection of KRAS mutations in
heterogeneous cancer specimens. Cancer Res. 71(8 Suppl): S30712011.
View Article : Google Scholar
|
|
37
|
Thobe MN, Um SL, Peek VL, Ballard DW,
Konicek BW, Credille KM, Ebert PJ, Donoho GP and Yan B: Detection
of KRAS mutations in circulating tumor cells (CTCs) and in
formalin-fixed, paraffin-embedded (FFPE) tissue using castPCR
method. Cancer Res. 72(8 Suppl): S20872012. View Article : Google Scholar
|
|
38
|
Wang K, Liu T, Ge N, Liu L, Yuan X, Liu J,
Kong F, Wang C, Ren H, Yan K, et al: TERT promoter mutations are
associated with distant metastases in upper tract urothelial
carcinomas and serve as urinary biomarkers detected by a sensitive
castPCR. Oncotarget. 5:12428–12439. 2014.
|
|
39
|
Bolton L, Reiman A, Lucas K, Timms J and
Cree IA: KRAS mutation analysis by PCR: A comparison of two
methods. PLoS One. 10:e01156722015. View Article : Google Scholar
|
|
40
|
Arena S, Bellosillo B, Siravegna G,
Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S,
González I, et al: Emergence of multiple EGFR extracellular
mutations during cetuximab treatment in colorectal cancer. Clin
Cancer Res. 21:2157–2166. 2015. View Article : Google Scholar
|
|
41
|
Mansuet-Lupo A, Zouiti F, Alifano M,
Tallet A, Charpentier MC, Ducruit V, Devez F, Lemaitre F,
Laurent-Puig P, Damotte D and Blons H: Intratumoral distribution of
EGFR mutations and copy number in metastatic lung cancer, what
impact on the initial molecular diagnosis? J Transl Med.
12:1312014. View Article : Google Scholar
|
|
42
|
Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen
CY, Chang KT, Chen YM, Perng RP, Tsai SF and Tsai CM: Mutation in
the tyrosine kinase domain of epidermal growth factor receptor is a
predictive and prognostic factor for gefitinib treatment in
patients with non-small cell lung cancer. Clin Cancer Res.
11:3750–3757. 2005. View Article : Google Scholar
|
|
43
|
Shi Y, Li J, Zhang S, Wang M, Yang S, Li
N, Wu G, Liu W, Liao G, Cai K, et al: Molecular epidemiology of
EGFR mutations in asian patients with advanced non-small-cell lung
cancer of adenocarcinoma histology-mainland China subset analysis
of the PIONEER study. PLoS One. 10:e01435152015. View Article : Google Scholar
|
|
44
|
Wu Y, Chu X, Wang J, Liu Z, Shen Y, Ma H,
Fu X, Hu J, Zhou N, Liu Y, et al: 1175OEGFR mutation and survival
outcomes in patients with completely resected lung adenocarcinoma-a
multiple centers, non-interventional study (ICAN TRIAL). Ann Oncol.
25(suppl 4): iv4102014. View Article : Google Scholar
|
|
45
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
46
|
Shigematsu H, Li L, Takahashi T, Nomura M,
Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–345. 2005. View Article : Google Scholar
|
|
47
|
Bareschino MA, Schettino C, Rossi A,
Maione P, Sacco PC, Zeppa R and Gridelli C: Treatment of advanced
non small cell lung cancer. J Thorac Dis. 3:122–133. 2011.
|
|
48
|
Maheswaran S, Sequist LV, Nagrath S, Ulkus
L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ,
Bell DW, et al: Detection of mutations in EGFR in circulating
lung-cancer cells. N Engl J Med. 359:366–377. 2008. View Article : Google Scholar
|
|
49
|
Hata A, Yoshioka H, Fujita S, Kunimasa K,
Kaji R, Imai Y, Tomii K, Iwasaku M, Nishiyama A, Ishida T and
Katakami N: Complex mutations in the epidermal growth factor
receptor gene in non-small cell lung cancer. J Thorac Oncol.
5:1524–1528. 2010. View Article : Google Scholar
|
|
50
|
Keam B, Kim DW, Park JH, Lee JO, Kim TM,
Lee SH, Chung DH and Heo DS: Rare and complex mutations of
epidermal growth factor receptor, and efficacy of tyrosine kinase
inhibitor in patients with non-small cell lung cancer. Int J Clin
Oncol. 19:594–600. 2014. View Article : Google Scholar
|
|
51
|
Masago K, Fujita S, Kim YH, Ichikawa M,
Hatachi Y, Fukuhara A, Nagai H, Irisa K, Mio T and Mishima M:
Epidermal growth factor receptor (EGFR) double-activating somatic
mutations in exons 19 and 21 in Japanese non-small cell lung cancer
patients. Cancer Genet Cytogenet. 195:179–182. 2009. View Article : Google Scholar
|
|
52
|
Masago K, Togashi Y, Fukudo M, Terada T,
Irisa K, Sakamori Y, Fujita S, Kim YH, Mio T, Inui KI and Mishima
M: Good clinical response to erlotinib in a non-small cell lung
cancer patient harboring multiple brain metastases and a double
active somatic epidermal growth factor gene mutation. Case Rep
Oncol. 3:98–105. 2010. View Article : Google Scholar
|
|
53
|
Peng L, Song ZG and Jiao SC: Efficacy
analysis of tyrosine kinase inhibitors on rare non-small cell lung
cancer patients harboring complex EGFR mutations. Sci Rep.
4:61042014. View Article : Google Scholar
|
|
54
|
Zhang GC, Lin JY, Wang Z, Zhou Q, Xu CR,
Zhu JQ, Wang K, Yang XN, Chen G, Yang JJ, et al: Epidermal growth
factor receptor double activating mutations involving both exons 19
and 21 exist in Chinese non-small cell lung cancer patients. Clin
Oncol (R Coll Radiol). 19:499–506. 2007. View Article : Google Scholar
|
|
55
|
Yang Y, Zhang B, Li R, Liu B and Wang L:
EGFR-tyrosine kinase inhibitor treatment in a patient with advanced
non-small cell lung cancer and concurrent exon 19 and 21 EGFR
mutations: A case report and review of the literature. Oncol Lett.
11:3546–3550. 2016. View Article : Google Scholar
|
|
56
|
Blakely CM, Lin L, Asthana S, Sidiropoulos
N, Nelson T, Bastian BC, Gubens MA, Taylor BS and Bivona TG:
Concurrent driver mutations in non-small cell lung cancer (NSCLC)
patients (p) on targeted therapy uncovered by comprehensive
molecular profiling. J Clin Oncol. 31(15 Suppl): S19042013.
|
|
57
|
Schmid K, Oehl N, Wrba F, Pirker R, Pirker
C and Filipits M: EGFR/KRAS/BRAF mutations in primary lung
adenocarcinomas and corresponding locoregional lymph node
metastases. Clin Cancer Res. 15:4554–4560. 2009. View Article : Google Scholar
|
|
58
|
Cardarella S, Ogino A, Nishino M, Butaney
M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE and Jänne PA:
Clinical, pathologic, and biologic features associated with BRAF
mutations in non-small cell lung cancer. Clin Cancer Res.
19:4532–4540. 2013. View Article : Google Scholar
|
|
59
|
Sasaki H, Shitara M, Yokota K, Okuda K,
Hikosaka Y, Moriyama S, Yano M and Fujii Y: Braf and erbB2
mutations correlate with smoking status in lung cancer patients.
Exp Ther Med. 3:771–775. 2012. View Article : Google Scholar
|
|
60
|
Kobayashi M, Sonobe M, Takahashi T,
Yoshizawa A, Ishikawa M, Kikuchi R, Okubo K, Huang CL and Date H:
Clinical significance of BRAF gene mutations in patients with
non-small cell lung cancer. Anticancer Res. 31:4619–4623. 2011.
|
|
61
|
Kinno T, Tsuta K, Shiraishi K, Mizukami T,
Suzuki M, Yoshida A, Suzuki K, Asamura H, Furuta K, Kohno T and
Kushima R: Clinicopathological features of nonsmall cell lung
carcinomas with BRAF mutations. Ann Oncol. 25:138–142. 2014.
View Article : Google Scholar
|
|
62
|
Brustugun OT, Khattak AM, Trømborg AK,
Mizukami T, Suzuki M, Yoshida A, Suzuki K, Asamura H, Furuta K,
Kohno T and Kushima R: BRAF-mutations in non-small cell lung
cancer. Lung Cancer. 84:36–38. 2014. View Article : Google Scholar
|
|
63
|
Zheng G, Tseng LH, Chen G, Haley L, Illei
P, Gocke CD, Eshleman JR9 and Lin MT: Clinical detection and
categorization of uncommon and concomitant mutations involving
BRAF. BMC Cancer. 15:7792015. View Article : Google Scholar
|
|
64
|
Gao J, Wu H, Shi X, Huo Z, Zhang J and
Liang Z: Comparison of next-generation sequencing, quantitative PCR
and sanger sequencing for mutation profiling of EGFR KRAS, PIK3CA
and BRAF in clinical lung tumors. Clin Lab. 62:689–696. 2016.
View Article : Google Scholar
|
|
65
|
Marchetti A, Felicioni L, Malatesta S,
Grazia Sciarrotta M, Guetti L, Chella A, Viola P, Pullara C,
Mucilli F and Buttitta F: Clinical features and outcome of patients
with non-small-cell lung cancer harboring BRAF mutations. J Clin
Oncol. 29:3574–3579. 2011. View Article : Google Scholar
|
|
66
|
Tissot C, Couraud S, Tanguy R, Bringuier
PP, Girard N and Souquet PJ: Clinical characteristics and outcome
of patients with lung cancer harboring BRAF mutations. Lung Cancer.
91:23–28. 2016. View Article : Google Scholar
|
|
67
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar
|
|
68
|
Leon SA, Shapiro B, Sklaroff DM and Yaros
MJ: Free DNA in the serum of cancer patients and the effect of
therapy. Cancer Res. 37:646–650. 1977.
|
|
69
|
Pratilas C, Hanrahan AJ, Halilovic E,
Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A,
Janakiraman M, et al: Genetic predictors of MEK-dependence in
non-small cell lung cancer. Cancer Res. 68:9375–9383. 2008.
View Article : Google Scholar
|
|
70
|
An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ,
Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, et al: Identification
of enriched driver gene alterations in subgroups of non-small cell
lung cancer patients based on histology and smoking status. PLoS
One. 7:e401092012. View Article : Google Scholar
|
|
71
|
Bahadoran P, Allegra M, Le Duff F,
Long-Mira E, Hofman P, Giacchero D, Passeron T, Lacour JP and
Ballotti R: Major clinical response to a BRAF inhibitor in a
patient with a BRAF L597R-mutated melanoma. J Clin Oncol.
31:e324–e326. 2013. View Article : Google Scholar
|
|
72
|
Sequist LV, Martins RG, Spigel D, Grunberg
SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky
A, et al: First-line gefitinib in patients with advanced
non-small-cell lung cancer harboring somatic EGFR mutations. J Clin
Oncol. 26:2442–2494. 2008. View Article : Google Scholar
|
|
73
|
Nakamura T, Sueoka-Aragane N, Iwanaga K,
Sato A, Komiya K, Abe T, Ureshino N, Hayashi S, Hosomi T, Hirai M,
et al: A noninvasive system for monitoring resistance to epidermal
growth factor receptor tyrosine kinase inhibitors with plasma DNA.
J Thorac Oncol. 6:1639–1648. 2011. View Article : Google Scholar
|
|
74
|
Rosell R, Molina MA, Costa C, Simonetti S,
Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P,
Cardenal F, et al: Pretreatment EGFR T790M mutation and BRCA1 mRNA
expression in erlotinib-treated advanced non-small-cell lung cancer
patients with EGFR mutations. Clin Cancer Res. 17:1160–1168. 2011.
View Article : Google Scholar
|
|
75
|
Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY
and Yang PC: Effectiveness of tyrosine kinase inhibitors on
‘uncommon’ epidermal growth factor receptor mutations of unknown
clinical significance in non-small cell lung cancer. Clin Cancer
Res. 17:3812–3821. 2011. View Article : Google Scholar
|
|
76
|
Fujita Y, Suda K, Kimura H, Matsumoto K,
Arao T, Nagai T, Saijo N, Yatabe Y, Mitsudomi T and Nishio K:
Highly sensitive detection of EGFR T790M mutation using colony
hybridization predicts favorable prognosis of patients with lung
cancer harboring activating EGFR mutation. J Thorac Oncol.
7:1640–1644. 2012. View Article : Google Scholar
|
|
77
|
Su KY, Chen HY, Li KC, Kuo ML, Yang JC,
Chan WK, Ho BC, Chang GC, Shih JY, Yu SL and Yang PC: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation predicts
shorter EGFR tyrosine kinase inhibitor response duration in
patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440.
2012. View Article : Google Scholar
|
|
78
|
Sakai K, Horiike A, Irwin DL, Kudo K,
Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani
N, et al: Detection of epidermal growth factor receptor T790M
mutation in plasma DNA from patients refractory to epidermal growth
factor receptor tyrosine kinase inhibitor. Cancer Sci.
104:1198–1204. 2013. View Article : Google Scholar
|
|
79
|
Costa C, Molina MA, Drozdowskyj A,
Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R,
Massuti B, Wei J, Moran T, et al: The impact of EGFR T790M
mutations and BIM mRNA expression on outcome in patients with
EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the
randomized phase III EURTAC trial. Clin Cancer Res. 20:2001–2002.
2014. View Article : Google Scholar
|
|
80
|
Yu HA, Arcila ME, Hellmann MD, Kris MG,
Ladanyi M and Riely GJ: Poor response to erlotinib in patients with
tumors containing baseline EGFR T790M mutations found by routine
clinical molecular testing. Ann Oncol. 25:423–428. 2014. View Article : Google Scholar
|
|
81
|
Miyazawa H, Tanaka T, Nagai Y, Matsuoka M,
Huqun, Sutani A, Udagawa K, Zhang J, Hirama T, Murayama Y, et al:
Peptide nucleic acid-locked nucleic acid polymerase chain reaction
clamp-based detection test for gefitinib-refractory T790M epidermal
growth factor receptor mutation. Cancer Science. 99:595–6600. 2008.
View Article : Google Scholar
|
|
82
|
Li J, Wang L, Jänne PA and Makrigiorgos
GM: Coamplification at lower denaturation temperature-PCR increases
mutation-detection selectivity of TaqMan-based real-time PCR. Clin
Chem. 55:748–756. 2009. View Article : Google Scholar
|
|
83
|
Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang
XC, Su J and Wu YL: Clinicopathologic and molecular features of
epidermal growth factor receptor T790M mutation and c-MET
amplification in tyrosine kinase inhibitor-resistant Chinese
non-small cell lung cancer. Pathol Oncol Res. 15:651–658. 2009.
View Article : Google Scholar
|
|
84
|
Oh YH, Kim Y, Kim YP, Seo SW, Mitsudomi T,
Ahn MJ, Park K and Kim HS: Rapid detection of the epidermal growth
factor receptor mutation in non-small-cell lung cancer for analysis
of acquired resistance using molecular beacons. J Mol Diagn.
12:644–652. 2010. View Article : Google Scholar
|
|
85
|
Oh JE, An CH, Yoo NJ and Lee SH: Detection
of low-level EGFR, T790M mutation in lung cancer tissues. APMIS.
119:403–411. 2011. View Article : Google Scholar
|
|
86
|
Taniguchi K, Uchida J, Nishino K, Kumagai
T, Okuyama T, Okami J, Higashiyama M, Kodama K, Imamura F and Kato
K: Quantitative detection of EGFR mutations in circulating tumor
DNA derived from lung adenocarcinomas. Clin Cancer Res.
17:7808–7815. 2011. View Article : Google Scholar
|
|
87
|
Arcila ME, Oxnard GR, Nafa K, Riely GJ,
Solomon SB, Zakowski MF, Kris MG, Pao W, Miller VA and Ladanyi M:
Rebiopsy of lung cancer patients with acquired resistance to EGFR
inhibitors and enhanced detection of the T790M mutation using a
locked nucleic acid-based assay. Clin Cancer Res. 17:1169–1180.
2011. View Article : Google Scholar
|
|
88
|
Guha M, Castellanos-Rizaldos E and
Makrigiorgos GM: DISSECT method using PNA-LNA clamp improves
detection of EGFR T790m mutation. PLoS One. 8:e677822013.
View Article : Google Scholar
|
|
89
|
He C, Zheng L, Xu Y, Liu M, Li Y and Xu J:
Highly sensitive and noninvasive detection of epidermal growth
factor receptor T790M mutation in non-small cell lung cancer. Clin
Chim Acta. 425:119–124. 2013. View Article : Google Scholar
|
|
90
|
Kim HJ, Oh SY, Kim WS, Kim SJ, Yoo GH, Kim
WD and Lee KY: Clinical investigation of EGFR mutation detection by
pyrosequencing in lung cancer patients. Oncol Lett. 5:271–276.
2013. View Article : Google Scholar
|
